Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "OPIOID TOLERANCE" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Analgesic tolerance refers to the diminishing analgesic effect of an opioid because of physiological adaptation to the opioid. Analgesic tolerance is not inevitable, but it does occur.
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER LAMBERT CO LLC
Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy
InactiveUS20150087613A1Reducing opioid antinociceptive toleranceReduced Tolerance RequirementsBiocideCarbohydrate active ingredientsPain therapyTolerability
Owner:SAINT LOUIS UNIVERSITY
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER-LAMBERT CO
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.< / PTEXT>
Owner:WARNER LAMBERT CO LLC
Chimeric hybrid analgesics
InactiveUS6881829B2Little and no developmentUndesirable side-effectNervous disorderAntipyreticTolerabilityWhole body
The present invention provides composition of matter for and methods of treating pain and drug abuse using novel chimeric hybrid molecules containing an opioid moiety of chemically modified morphine (3) that binds to and activates the human mu (μ) opioid receptor, with the opioid moiety linked through a novel linker-hinge (4) to a substance P peptide fragment moiety (5) that binds to and activates the human substance P receptor. The hybrid alkaloid / peptide chimeric molecules produce clinically efficacious opioid analgesia with little or no development of opioid tolerance or formation of opioid dependence. The hybrid alkaloid / peptide analgesics may be administered intrathecally, systemically or orally.
Owner:CHIMERACOM LLC
Compositions and method for enhancing the therapeutic activity of opioids in treatment of pain
Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Application of stilbene glycoside to preparing analgesic medicine
InactiveCN105030799ARich sourcesImprove securityNervous disorderAntipyreticOpioid useGlycoside formation
The invention discloses novel application of stilbene glycoside to the field of analgesic medicine, and particularly discloses application of stilbene glycoside to preparing medicine for enhancing analgesic effects of opioid medicine and delaying or relieving opioid tolerance. The application has the advantages that the stilbene glycoside is used with the opioid medicine, or compound preparations are made of the stilbene glycoside and the opioid medicine, so that the analgesic time can be prolonged, the analgesic efficacy can be enhanced, and opioid tolerance during chronic opioid medicine treatment procedures can be delayed or relieved; excessive activation of spinal glial cells induced by the opioid medicine is particularly suppressed by the stilbene glycoside, so that effects can be realized.
Owner:JIANGSU TIANSHENG PHARMA
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitor compounds of formula (I) and use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER-LAMBERT CO
Methods of attenuating opioid tolerance
InactiveUS20150246074A1Relieve painOrganic active ingredientsBiocideTolerabilityMesenchymal stem cell
Disclosed are methods of reducing pain and / or preventing or reducing opioid tolerance in a subject by administering to the subject mesenchymal stem cells.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Novel application of paeoniflorin in field of analgesics
InactiveCN103768083AImprove securityGood analgesic effectOrganic active ingredientsNervous disorderOpioid useBiological activation
The invention discloses novel application of paeoniflorin in the field of analgesics, and in particular relates to application of paeoniflorin in preparation of a medicine for reinforcing the analgesic effect of opioid medicines, and retarding or reducing the opioid tolerance. The application of paeoniflorin matched with opioid medicines or compound preparation prepared from paeoniflorin and opioid medicines can be used for prolonging the analgesic time of opioid medicines and strengthening the analgesic effect of opioid medicines, and can retard or reduce the opioid tolerance phenomenon in the treatment process of opioid medicines. The effect can be realized by using p-P38 of paeoniflorin in inhibiting opioid medicine induced over activation of spinal microglial cells and inhibiting opioid induced over up-regulation.
Owner:SHANGHAI TANGGUO MEDICAL TECH CO LTD
CDL (corydalmine) medicine composition for preventing and treating opioid analgesic pain relieving tolerance
InactiveCN105878239AGood analgesic effectDelay or lessen toleranceOrganic active ingredientsAntipyreticTolerabilitySpinal cord
The present invention discloses the new application of Corydalis CDL (CDL) in the field of analgesic drugs, and specifically discloses the application of CDL in the preparation of drugs for preventing or treating analgesic tolerance of opioid analgesic drugs. The corydalis dammine is used in combination with opioids, or used in compound preparations with opioids, which can enhance its analgesic effect and prevent or alleviate opioid tolerance in the course of chronic opioid treatment. This effect is achieved by inhibiting opioid-induced excessive activation of spinal cord microglial cells, and inhibiting opioid-induced excessive up-regulation of p-P38, p-ERK and p-JNK.
Owner:CHINA PHARM UNIV +1
Endothelin Receptors In Morphine Withdrawal
InactiveUS20090221490A1Improve toleranceEasy to manageOrganic active ingredientsNervous disorderTolerabilityMedicine
The present invention relates to compositions and methods for managing opioid tolerance and reducing opioid withdrawal. More specifically, the present invention provides for endothelin, endothelin receptors, and endothelin receptor antagonists and agonists as a means for managing G-protein activity in the context of opioid tolerance and withdrawal.
Owner:GULATI ANIL +1
Application of puerarin to preparing pain easing medicine
InactiveCN104940190ARich sourcesImprove securityOrganic active ingredientsNervous disorderOpioid useOPIOID TOLERANCE
The invention discloses new application of puerarin to preparing a pain easing medicine, and particularly discloses the application of the puerarin to preparing the medicine for strengthening the opioid medicine pain easing effect and delaying or alleviating the opioid tolerance. When the puerarin is matched with an opioid medicine to be used, or the puerarin and the opioid medicine are prepared into a compound preparation to be used, the pain easing time of the medicine can be prolonged, the pain easing efficiency can be strengthened, and the opioid tolerance in the opioid medicine treatment process can be further delayed or alleviated. The effect is specifically achieved by restraining spinal glial cell overactivity induced by the opioid medicine through the puerarin.
Owner:JIANGSU TIANSHENG PHARMA
Methods of Treatment of Opioid Tolerance, Physical Dependence, Pain and Addiction With Inhibitors of Certain Growth Factor Receptors
InactiveUS20100210709A1Preventing and reducing and reversing opioid toleranceCombination therapy can be facilitatedBiocideOrganic active ingredientsPhysical dependenceMedicine
Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The methods can also be used for the treatment of refractory neuropathic pain, physical dependence or addiction.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Compositions and methods for treating opioid tolerance
ActiveUS20180362607A1Organic active ingredientsPeptide/protein ingredientsTolerabilityMorphine tolerance
The present disclosure is directed to a method of treating morphine tolerance and / or symptoms associated therewith by administration to a subject in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.
Owner:GEORGIA STATE UNIV RES FOUND INC
Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
InactiveUS8501740B2Preventing, reducing and/or reversing opioid toleranceCombination therapy can be facilitatedOrganic active ingredientsBiocidePhysical dependenceMedicine
Methods of preventing the development and reversing or partially reversing opioid tolerance in a subject are provided herein. Such methods include the step of administering to a subject in need thereof a therapeutically effective amount of a PDGFR modulator or EGFR modulator alone or together with an opiate analgesic. The methods can also be used for the treatment of refractory neuropathic pain, physical dependence or addiction.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:WARNER-LAMBERT CO
Compositions and method for enhancing the therapeutic activity of opiods in treatment of pain
Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
Owner:HU LAIN YEN +4
Endothelin Receptors in Morphine Withdrawal
InactiveUS20100323456A1Easy to manageEasy to understandOrganic active ingredientsMaterial analysisTolerabilityMorphine withdrawal
Owner:GULATI ANIL +1
Application of seabuckthorn flavonoids in the preparation of compositions for enhancing the efficacy of opioids
ActiveCN105030851BProlonged analgesic timeGood analgesic effectOrganic active ingredientsNervous disorderDrug effectProlongation
Owner:JIANGSU TIANSHENG PHARMA
New application of ligustrazine in field of analgesic drugs
InactiveCN104739832AImprove securityGood analgesic effectOrganic active ingredientsNervous disorderAnalgesics drugsOpioid use
The invention discloses a new application of ligustrazine in the field of analgesic drugs, and particularly discloses an application of the ligustrazine in preparation of medicines for enhancing the analgesic effect of opioid agents, and delaying or relieving the opioid tolerance. The ligustrazine is matched with the opioid agents for use, or is prepared into a compound preparation together with the opioid agents for use; the analgesic time can be prolonged; the analgesic effect can be enhanced; the phenomenon of opioid tolerance caused in the treatment process of the chronic opioid agents can also be delayed or relieved; and the ligustrazine has the specific effects of inhibiting excessive activation of spinal microglia induced by the opioid agents through the ligustrazine and inhibiting realization of excessive increase p-P38 induced by opioid.
Owner:NANJING MEDICAL UNIV
Methods of using cannabinoid cb2 receptor agonist compositions to suppress and prevent opioid tolerance and withdrawal in a subject
InactiveUS20190314379A1Nervous disorderHeterocyclic compound active ingredientsPhysical dependenceCannabinoid
The present disclosure relates to methods of using cannabinoid CB2 receptor agonist compositions to suppress pain (e.g., neuropathic pain), opioid tolerance, and / or opioid-induced physical dependence in a subject.
Owner:INDIANA UNIV RES & TECH CORP
Methods and compositions for maintaining opioid efficacy in the treatment of pain
ActiveUS20200316057A1Reducing risk of opioid addiction and dependenceReduce addictionOrganic active ingredientsNervous disorderManaged painEfficacy
The present invention provides methods for treating and / or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.
Owner:EAST CAROLINA UNIVERISTY
Analgesia method
InactiveUS20090023697A1Reducing opioid toleranceOrganic active ingredientsNervous disorderMedicineOPIOID TOLERANCE
Opioid tolerance is reduced by treating the patient with a neurosteroid of formula (I) wherein R1 is H or methyl; R2 is OH and R3 is H, or R2 and R3 taken together are O; R4 is H or methyl; R5 and R6 are each H, or R5 and R5 taken together are O; R7 is H or methyl; and R8 is H, OH, —OC(═O)CH3, SH, —SC(═O)CH3, Cl, Br or F.
Owner:VERNALIS (R&D) LTD
Application of matrine in preparing opioid
InactiveCN104940199ARich sourcesImprove securityOrganic active ingredientsNervous disorderAnalgesics drugsMatrine
The invention discloses new application of matrine in the field of analgesic drugs, and particularly discloses application of matrine in preparing drugs enhancing the analgesic effect of opioid, and delaying or relieving opioid tolerance. The matrine is matched with the opioid for use, or the matrine and the opioid are prepared into compound preparations for use, the analgesia time of the opioid can be prolonged, the analgesic efficacy of the opioid can be enhanced, and the opioid tolerance phenomenon happening in the treating process of opioid slow in taking effect can also be delayed or relieved. Specifically, the effect is achieved in the mode that the matrine is used for inhibiting excessive activation, induced by the opioid, of spinal cord glial cells.
Owner:JIANGSU TIANSHENG PHARMA
D-amino-acid oxidase inhibitor for preventing and/or reversing opioid tolerance
InactiveCN102727896AOrganic active ingredientsNervous disorderOPIOID TOLERANCEMonoamine oxidase inhibitor
The invention provides a D-amino-acid oxidase inhibitor for preventing and / or reversing opioid tolerance and a method for preventing or reversing opioid tolerance by the use of the D-amino-acid oxidase inhibitor, and also provides a method for preventing and / or treating ache by the use of the D-amino-acid oxidase inhibitor and a method for identifying the compound for preventing and / or reversing opioid tolerance.
Owner:王永祥
Application of seabuckthorn flavone in preparation of compositions for enhancing drug effect of opioids
ActiveCN105030851AProlonged analgesic timeGood analgesic effectOrganic active ingredientsNervous disorderDrug effectProlongation
The invention discloses an application of seabuckthorn flavone in the preparation of compositions for enhancing the drug effect of opioids. Compared with applications in the prior art, the application has the advantages of substantial prolongation of the pain easing time of the opioids, enhancement of the pain easing effect of the opioids, and delaying of opioid tolerance caused by the opioids through synergism realized by common use of the seabuckthorn flavone and the opioids.
Owner:JIANGSU TIANSHENG PHARMA
Method for treating cancer pain and/or rescuing analgesic effect of morphine treatment of cancer pain
InactiveUS20130108628A1Reducing opioid toleranceRescuing analgesic effectNervous disorderPeptide/protein ingredientsEphB ReceptorTolerability
The present invention provides a method for treating cancer pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. Also provided is a method for reducing opioid tolerance in treating cancer pain thereby rescuing analgesic effect of morphine treatment of cancer pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. The blocking reagent can be an EphB receptor blocker such as EphB1-Fc and EphB2-Fc.
Owner:PARKER UNIV
Methods and Compositions for Maintaining Opioid Efficacy in the Treatment of Pain
PendingUS20220110932A1Reducing risk of opioid addiction and dependenceReduce addictionOrganic active ingredientsNervous disorderManaged painEfficacy
Owner:EAST CAROLINA UNIVERISTY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com